학술논문
Epcoritamab (epco) with gemcitabine plus oxaliplatin (GemOx) in patients (pts) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) ineligible for autologous stem cell transplant (ASCT) induces high response rate even in pts failing CAR T therapy.
Document Type
ConferencePaper
Author
Source
JOURNAL OF CLINICAL ONCOLOGY. 40(16)
Subject
Language
English
English
English
ISSN
0732-183X